The Neurocognitive (Neuro) Genetic panel examines 35 different genes associated with the elevated risk of neurocognitive disorder development. It detects diagnostic risk factors associated with the genes for Alzheimer’s disease, Parkinson’s disease and Dementia.

Unfortunately, a diagnostic test for dementia still does not exist. By choosing Neuro testing, patients can rule out medical conditions that mimic memory loss symptoms typically associated with dementia, making it a vital tool in the overall diagnostic process.

Parkinson’s disease can run in families as a result of faulty genes passed to children from their parents. Around 15% of all Parkinson’s diagnoses have family histories of the disorder, making the PAD an important choice for those with family members who have Parkinson’s.

Alzheimer’s, or early-onset familial Alzheimer’s disease (FAD), affects approximately 5% cases.

Any patient experiencing changes in their mood or personality, difficulty completing routine tasks, trouble moving or controlling movements, and/or memory loss, confusion of the time/place and those with abnormal brain imaging results should seek immediate testing. Additionally, Risk factors include:

-High Blood Pressure
-High Cholesterol
-Diabetes
-Genetic Etiology
-APOE Genotype

Early detection of Neuro pathogenic genes leads to a more intensive planning and decision-making process, and peace of mind in creating a medical treatment plan, seeking psychosocial counseling, and future family risk assessment. Some patients also choose to participate in medical research studies in hopes of finding new cures.